RCS - Ondine Biomedical - Ondine to present poster at IP2023, Liverpool

Ondine BiomedicalAnnouncement

10/10/2023 09:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231010:nRSJ6266Pa&default-theme=true

RNS Number : 6266P  Ondine Biomedical Inc.  10 October 2023

10 October 2023

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

Ondine to present poster at IP2023 meeting, Liverpool

Ondine Biomedical will be presenting new research at the Infection Prevention
Society 2023 Conference in Liverpool, UK

Canadian life sciences company Ondine Biomedical Inc. (LON: OBI) will present
results from a new in vitro study at the IP2023 Annual Conference
(https://ip2023conference.net/) taking place in Liverpool from 17-19 October
2023. The study evaluated the efficacy of antimicrobial photodynamic therapy
(aPDT, also known as photodisinfection) against multidrug-resistant (MDR) and
extensively drug-resistant (XDR) bacteria. IP2023 is organized by the
Infection Prevention Society (https://www.ips.uk.net/about) and is the largest
annual infection prevention conference in the UK and Ireland.

Antimicrobial resistance (AMR) remains a major public health concern, causing
33,000 deaths in Europe annually. 1  (#_edn1) There are widespread
multidrug-resistant (MDR) and extensively drug-resistant (XDR) infections in
Europe, mainly caused by Gram-negative bacteria including Enterobacteriaceae
and P. aeruginosa AMR bacteria 2  (#_edn2) (, 3  (#_edn3) ) and Gram-positive
bacteria such as Staphylococcus spp. 4  (#_edn4)

Photodisinfection uses a photosensitizer and a specific wavelength of light to
trigger photochemical reactions that produce reactive oxygen species. These
reactive oxygen species are lethal to a broad spectrum of microbes, including
bacteria, fungi, and viruses. Importantly, photodisinfection does not induce
antimicrobial resistance formation.

Photodisinfection is an easy-to-use alternative to topical antibiotics and
antifungals because it is highly effective against all types of
disease-causing pathogens, including MDR and XDR strains.

The poster presentation, "Antimicrobial Photodynamic Therapy Against
Extensively Drug-Resistant (XDR) Gram Negative Isolates With Novel Antibiotic
Resistance Factors", will be presented at IP2023 between 1:10pm and 2:40pm
(BST) on 18 October 2023. A further announcement providing more details of the
research will be released by the Company concurrent with the start of the
presentation.

 

 Ondine Biomedical Inc.
 Carolyn Cross, CEO                                           +001 (604) 665 0555

 Singer Capital Markets (Nominated Adviser and Joint Broker)
 Aubrey Powell, Asha Chotai, Sam Butcher                      +44 (0)20 7496 3000

 RBC Capital Markets (Joint Broker)
 Rupert Walford, Kathryn Deegan                               +44 (0)20 7653 4000

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy, Amanda Bernard                             +44 (0)77 1000 5910

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian headquartered company innovating in the
field of photodisinfection therapies. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection platform, in various
stages of development. Products beyond nasal photodisinfection include
therapies for a variety of medical indications such as chronic sinusitis,
ventilator-associated pneumonia, burns, and other indications.

 

 

 1  (#_ednref1) WHO Regional Office for Europe/European Centre for Disease
Prevention and Control. Antimicrobial resistance surveillance in Europe 2022 -
2020 data. Copenhagen: WHO Regional Office for Europe; 2022.

 2  (#_ednref2) Cassini A, Högberg LD, Plachouras D, et al. Attributable
deaths and disability-adjusted life-years caused by infections with
antibiotic-resistant bacteria in the EU and the European Economic Area in
2015: a population-level modelling analysis. Lancet Infect Dis.
2019;19(1):56-66. doi:10.1016/S1473-3099(18)30605-4

 3  (#_ednref3) Karakonstantis S, Kritsotakis EI, Gikas A. Pandrug-resistant
Gram-negative bacteria: a systematic review of current epidemiology, prognosis
and treatment options. J Antimicrob Chemother. 2020;75(2):271-282.
doi:10.1093/jac/dkz401

 4  (#_ednref4) UK Health Security Agency. MRSA, MSSA, Gram-negative
bacteraemia and CDI: 30-day all-cause fatality, London: UK Health Security
Agency, March 2023.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRANKKBPOBDKAKD